Clinical Trial Update: Phase IV Study of Tarceva in Patients With Advanced Stage IIIB/ IV Non-small Cell Lung Cancer (NSCLC)

View source ↗

Summary

A Phase IV study evaluating erlotinib (Tarceva) in patients with advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: University of Athens | Conditions: Non-small Cell Lung Cancer | Status: COMPLETED